Ginnalin A and SB203580 show additive effect on Hep-3B hepatocellular carcinoma cell line

Creative Commons License

Vural H., Özden P., Avcı E.

Turkish Journal of Biochemistry, vol.44, no.1, pp.78-85, 2019 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 44 Issue: 1
  • Publication Date: 2019
  • Doi Number: 10.1515/tjb-2018-0099
  • Journal Name: Turkish Journal of Biochemistry
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.78-85
  • Keywords: Additive effect, Caspase-3 activity, Ginnalin A, Hepatocellular carcinoma, SB203580
  • Yozgat Bozok University Affiliated: No


Objective: Investigation of the anticarcinogenic effects of natural products with low toxicity is very important in the development of new therapeutic strategies against cancer. Ginnalin A (GA) is one of the most important phenolic compounds of Acer genus and its anticancer effect has been shown that in various cancer cell lines. SB203580, a p38 MAPK inhibitor, can inhibit cell proliferation independently of p38 MAPK. The objective of this study was to investigate combination effect of GA and SB203580 on Hep-3B cell line. Material and methods: Cell viability was determined by using XTT method after the treatment with GA, SB203580 and combination of both. Anticarcinogenic effects of GA and SB203580 both in single and in combination have been analyzed with Caspase-3 activity assay and expression levels of important genes involved in cell cycle and apoptosis were evaluated by qPCR. Results: GA and SB203580 have shown additive effect on Hep-3B cells in the combination inhibited 50% of cell viability. And, SB203580 increased the effect of GA on activation of Caspase-3 and expressions of genes important in apoptosis and cell cycle. Conclusion: This study indicates that GA and SB203580 can be an effective for development of new therapeutic strategies in hepatocellular carcinoma.